The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to

Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials - ScienceDirect

Targeted therapy for rare lung cancers: Status, challenges, and prospects - ScienceDirect

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC

A highly multiplexed quantitative phosphosite assay for biology and preclinical studies

Igor Odintsov's research works Brigham and Women's Hospital

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Sudarshan Iyer's research works

PROTAC therapy as a new targeted therapy for lung cancer - ScienceDirect

Functional significance of U2AF1 S34F in relation to SLC34A2-ROS1

A highly multiplexed quantitative phosphosite assay for biology and preclinical studies